Eczema (Atopic Dermatitis) Clinical Trials in Cincinnati
View 17 new treatments for Eczema (Atopic Dermatitis) in Cincinnati, OH. Every day, Power helps hundreds of Eczema (Atopic Dermatitis) patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Transcriptomic Skin Analysis for Atopic Dermatitis
Research Clinic, Cincinnati + 1 more
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Max A. Seibold, Ph.D.
Study Chair
Nemolizumab for Eczema
Galderma Clinic, Cincinnati + 1 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Amlitelimab for Atopic Dermatitis (COAST 2)
Sanofi Clinic, Cincinnati + 1 more
This trial tests amlitelimab injections for patients aged 12 and older with moderate to severe atopic dermatitis that isn't controlled by topical treatments. The injections aim to reduce inflammation and symptoms by targeting specific immune pathways.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Rocatinlimab for Atopic Dermatitis/Eczema
Amgen Clinic, Cincinnati + 1 more
This trial is testing rocatinlimab to see if it is safe and can be tolerated by people with moderate-to-severe eczema. The medication works by calming the immune system to reduce skin inflammation and irritation.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
MD
Study Director
Povorcitinib for Prurigo Nodularis
Incyte Clinic, Dayton + 1 more
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Recruiting
Phase 3
Est. 3 - 12 Weeks
Incyte Medical Monitor
Study Director
Povorcitinib for Prurigo Nodularis
Incyte Clinic, Cincinnati + 1 more
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Recruiting
Phase 3
Est. 3 - 6 Weeks
Incyte Medical Monitor
Study Director
Nemolizumab for Prurigo Nodularis
Galderma Clinic, Cincinnati + 1 more
This trial is testing the safety of nemolizumab, a medication for people with prurigo nodularis. Prurigo nodularis is a skin condition that causes itchy, hard lumps. Nemolizumab aims to reduce itching and swelling by blocking certain signals in the body.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Barzolvolimab for Prurigo Nodularis
Celldex Clinic, Cincinnati + 1 more
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Recruiting
Phase 2
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Skin Barrier Cream + Fluticasone Propionate for Eczema
Research Clinic, Cincinnati + 1 more
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeram™ has been previously tested for preventing eczema in infants with a family history of allergic disease.Show More
Recruiting
No Placebo Trial
Phase 2
Est. 3 - 6 Weeks
Kari Nadeau, MD, PhD
Principal Investigator
Amlitelimab for Atopic Dermatitis/Eczema
Sanofi Clinic, Cincinnati + 1 more
This trial tests amlitelimab, a medication that may help adults with moderate-to-severe atopic dermatitis respond better to vaccines. It works by improving how the immune system functions.Show More
Recruiting
Phase 2
Est. 5 - 8 Weeks
Clinical Sciences & Operations
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions